Anteris Technologies GlobalASX:AVR +10.05%50 FCF Yield % is -7.89 as of Jun. 24, 2026. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 7 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 72.51% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Anteris Technologies Global's FCF Yield % or its related term are showing as below:
ASX:AVR'
s FCF Yield % Range Over the Past 10 Years
Min: -76.98 Med: -44.23 Max: -7.89
Current: -7.89
During the past 13 years, the highest FCF Yield % of Anteris Technologies Global was -7.89%. The lowest was -76.98%. And the median was -44.23%.
ASX:AVR's FCF Yield % is ranked worse than 72.51% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: -0.38
vs ASX:AVR: -7.89
Anteris Technologies Global FCF Yield % Explanation
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Anteris Technologies Global FCF Yield % Related Terms
Anteris Technologies Global FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVR vs INMD, QDEL, SSII: FCF Yield % Comparison
For the Medical Devices subindustry, Anteris Technologies Global's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global (ASX:AVR) has a FCF Yield % of -7.89 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #620 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 72.5%.
Is Anteris Technologies Global's FCF Yield % too high?
Anteris Technologies Global's current FCF Yield % is -7.89. Based on the distribution chart, Anteris Technologies Global ranks #620 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's FCF Yield % compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #620 out of 855 companies for FCF Yield %. This places Anteris Technologies Global in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Anteris Technologies Global and its competitors. Anteris Technologies Global's current FCF Yield % is -7.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current FCF Yield % of -7.89. The current FCF Yield % is -7.89. Anteris Technologies Global's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current FCF Yield % is -7.89 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score
Get the complete analysis for ASX:AVR
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
